Cullinan And Taiho Post 14.5-Month PFS For Zipalertinib Combo, Pressing Rybrevant In EGFR Exon 20 NSCLC

Cullinan Therapeutics and Taiho Oncology have produced the detailed phase 3 dataset they needed to position zipalertinib as a first-line contender in EGFR exon 20 insertion mutation-positive non-small cell lung cancer. In the planned interim analysis from Rezilient3, adding the tyrosine kinase inhibitor to platinum-based chemotherapy extended median progression-free survival to 14.5 months from 8.5 months with chemotherapy alone.

That six-month improvement matters because this subset has already become a competitive commercial niche after Johnson & Johnson moved Rybrevant into the first-line setting. The new readout does not offer a head-to-head comparison, but it gives Taiho and Cullinan a numerically stronger progression-free survival figure than the 11.4 months cited for Rybrevant's approval, which is enough to sharpen the strategic case for a differentiated entry.

The data

Rezilient3 enrolled 279 adults with previously untreated, locally advanced or metastatic NSCLC carrying EGFR exon 20 insertion mutations. The combination arm delivered a statistically significant median progression-free survival of 14.5 months versus 8.5 months for chemotherapy alone.

The efficacy advantage extended beyond the primary endpoint. Objective response rate was 65% with zipalertinib plus chemotherapy, compared with 40.3% in the control cohort. Median duration of response was 14.2 months in the combination group and 9.9 months in the chemotherapy-only arm.

Overall survival remains immature, but the companies said the regimen has shown early promise with a hazard ratio for death of 0.72 versus control. Jeffrey Jones, Cullinan's chief medical officer, said that measure will continue to be followed with other secondary endpoints to better characterize survival.

Safety is the main tradeoff in the package. Grade 3 or higher adverse events occurred in 87.1% of patients on the combination regimen, compared with 54.4% in the control arm. The companies said these were primarily manageable hematologic adverse events. Grade 3 or higher events considered EGFR-related were described as infrequent, with rash the most common at 10.7% in the zipalertinib arm. Jones said most adverse events that led to discontinuation were attributable to the platinum chemotherapy and occurred in the first four months, when patients were receiving that treatment.

The commercial picture

This market has already seen one targeted therapy stumble and another capitalize. Takeda withdrew Exkivity from the U.S. market for adult NSCLC in 2023 after the drug missed a confirmatory study. J&J then secured approval for Rybrevant as a first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations, after an earlier 2021 FDA approval in the second-line setting.

Zipalertinib's commercial argument rests on being an oral next-generation small molecule designed to target activating EGFR mutations by irreversibly binding to exon 20. Jones contrasted that mechanism with AstraZeneca's Tagrisso, saying Tagrisso blocks EGFR but does not have much clinical activity at exon 20. If regulators accept the front-line dataset, Taiho and Cullinan could enter the market with an oral option supported by a meaningful progression-free survival benefit.

The patient pool is defined but material. NSCLC accounts for 80% to 87% of lung cancer diagnoses, and Jones said EGFR mutations occur in nearly one third of NSCLC patients, with about 4% involving an exon 20 insertion mutation in advanced disease. That is small compared with broader NSCLC segments, but targeted oncology markets do not need large populations to matter if the clinical proposition is credible.

The road here

The FDA has already accepted zipalertinib for review in NSCLC patients with EGFR exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy, and a decision in that later-line setting is expected next February. Taiho now plans to present the new front-line results to global health authorities and the FDA.

Cullinan also has clear financial exposure to the outcome. Under its 2022 deal with Taiho, the company is set to receive $30 million when zipalertinib is approved for second-line use and $100 million when it wins a first-line FDA approval. The partners will split pretax profits from U.S. sales equally.

The signal in the phase 3 readout is that zipalertinib is no longer just a later-line review story. Taiho and Cullinan now have data that could support a broader market position, and in a mutation-defined setting where sequencing and convenience influence uptake, an oral TKI with front-line efficacy can reshape how much room remains for an infused incumbent.